MaRS Business of Aging Summit 2012

The Business of Aging: Wellness in the Workplace A very important topic for our age (pardon the pun). Type A Events was thrilled to once again work with the insightful folks at MaRS Discovery District on their recent Business of Aging Summit 2012. Held in the main MaRS Auditorium, this packed agenda included two keynotes, an Innovation Showcase, 2 panels, 5 Innovation Vignettes, a case study, and an innovation implementation facilitation session. Did I mention this was a 1-day Summit? Our 2 keynotes Dr. Joseph Coughlin, Director, MIT AgeLab and Geoff Mulgan, CEO, NESTA (UK) book-ended this incredible day. Thanks to Dr. Alain Sotto, Chief Physician-Wellness Division at the OPG and Occupational Medical Consultant at the TTC for his thought-provoking case study; and to all our Innovators who are leading the charge in the new understanding of aging in the workplace.

The Summit's packed Agenda!

Innovation Showcase participant INTERxVENT

Keynote Dr. Joseph Coughlin, Director, MIT AgeLab holds his audience captive.

Ready for Lunch! Bento Boxes for all!

Keynote Dr. Joseph Coughlin, Director,MIT AgeLab
 "Thanks so much for your help, good cheer and effectiveness at the event. It was great to work with you and hope to have the chance again sometime soon. All the best, Joe"

For more photos visit the Type A Events Facebook page and the MaRS Discovery District blog on the event.

MaRS Business of Aging Summit

Type A Events is happy to be working again with the amazing people at MaRS.

The MaRS Business of Aging Summit will address age-related issues from the perspective of Care, Career, and Caregiving. A MUST ATTEND event for all in the age-related fields--which is all of us!

Dr. Joseph Coughlin, Director of MITs Institute of Technology Age Lab will be the keynote.

Click here for more information on this incredible summit and to register.

Post-Event: MaRS Discovery District: Nitric Oxide Symposium

Thank you again to the wonderful folk at MaRS Discovery District and at NeurAxon for their fantastic work during the recent Nitric Oxide and other Gaseous Neurotransmitter (NOX) Symposium. The gathering of 20 of the leading minds in the field, including Noble Laureate Dr. Ferid Murad, was the first of it's kind in Toronto-are we next in line for the crown of Canada's premiere BioTech city? I hope so--if only to have more quality Symposiums such as NOX, and in order for there to be opportunity for me to work with this great collection of people again!

For more information on MaRS Discovery District and the amazing work they do there please visit www.marsdd.com

The pioneering folk at NeurAxon can be found at www.neuraxon.com

MaRS Discovery District: Nitric Oxide Symposium

Type A Events is proud to be part of the coordination team for the Nitric Oxide Symposium presented by MaRS Discovery District and NeurAxon taking place on May 27th and 28th, 2010.

Following the Nobel Prize awarded in 1998 for the discovery and function of Nitric Oxide (which up until then had been regarded as a noxious gas) an enormous amount of research has been undertaken to better understand the functions of this neurotransmitter in various physiological conditions as well as acute and chronic pathological conditions such as pain, Parkinson’s disease, Alzheimer’s disease, traumatic brain injury, stroke, inflammatory disease etc. Apart from Nitric Oxide, two other gaseous neurotransmitters, Hydrogen Sulfide and Carbon Monoxide, have become the focus of biologists and chemists alike to explore the significance of these neurotransmitters in inflammation and gastric mucosal protection.

The objective of this symposium is to increase awareness amongst the research community as to how basic science driven approaches can lead to the successful development of novel therapeutic agents.

The following aspects will be covered:

• Biology: Discovery and function of gaseous neurotransmitters and mediators, including hydrogen sulfide and carbon monoxide
• Pharmacology: Pain, inflammation, immunology, CNS, TBI
• Structure: X-Ray structures on ligand bound enzymes
• Chemistry: Donors and inhibitors - therapeutic implications
• Clinical applications

For further information and registration please click here.